



H&T PRESSPART

PRESS RELEASE



SBTi Approves H&T Presspart's Climate Targets

Marsberg, Germany, 14th May, 2025 – H&T Presspart (a division of the Heitkamp & Thumann Group), a leading developer and manufacturer of drug delivery components and devices for the pharmaceutical market, is pleased to announce that our climate targets have been officially validated and approved by the Science-Based Targets initiative (SBTi). The SBTi commends our net-zero target, currently the most ambitious designation available through the SBTi process.

Validation and approval of climate targets by the independent, globally recognized Science Based Targets initiative is currently considered the 'gold standard'. With this step, H&T Presspart is reinforcing its commitment to combat climate change and to a science-based decarbonisation strategy with transparent reporting on the associated targets, progress and measures.

H&T Presspart's Climate Targets

Overall Net-Zero Target: H&T Presspart commits to reach net-zero greenhouse gas emissions across the value chain by 2050.

Near-Term Targets: H&T Presspart commits to reduce absolute scope 1 and 2 GHG emissions 58.8% by 2034 from a 2022 base year. H&T Presspart also commits to reduce scope 3 GHG emissions 63.8% per EUR value added within the same timeframe.

Long-Term Targets: H&T Presspart commits to reduce absolute scope 1 and 2 GHG emissions 90% by 2050 from a 2022 base year. H&T Presspart also commits to reduce scope 3 GHG emissions 97% per EUR value added within the same timeframe.

Christian Krätzig, President of the H&T Presspart Division, commented "I am very pleased to see that our climate targets have been validated and approved by the SBTi. This milestone underlines our leadership in sustainability and sets us apart in the industry. In line with the defined climate targets, we will continue to drive forward the decarbonisation of our organisation and along the value chain together with our valued partners."

----- The End -----

About H&T Presspart

H&T Presspart is a leading developer and manufacturer of drug delivery devices and components. With over 50 years of experience, it has built a global reputation for expertise, quality, and innovation in the pharmaceutical industry. With a wide portfolio of components, device solutions and services, H&T Presspart partners to deliver exceptional customer experience and accelerated routes to market of customers' drug-device programs. H&T Presspart has 4 European manufacturing sites in Germany, Spain, Switzerland, and the UK and has sales representation in China, India, the U.S.A., and Uruguay. For more information, please visit www.presspart.com.

Media Contact

Inga Meyer
Director of Strategy & Marketing
Inga.meyer@presspart.com